AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Butamben works by blocking the transmission of nerve impulses in the vicinity of its application. This results in temporary loss of sensation in the area where it is applied, providing pain relief during medical procedures or minor surgical interventions.
Topical Application: Butamben is typically available in the form of a topical cream or gel for external use on the skin or mucous membranes. It is applied directly to the area requiring anesthesia, allowing for targeted and localized pain relief.
Minor Surgical Procedures: Butamben is commonly used by healthcare professionals to provide local anesthesia for minor surgical procedures, such as suturing wounds, removing small skin lesions, or performing dermatological procedures.
Dental Procedures: Butamben may also be used in dentistry to provide local anesthesia for procedures such as dental fillings, tooth extractions, or periodontal treatments. Its rapid onset and short duration of action make it suitable for dental use.
Rapid Onset of Action: Butamben typically has a rapid onset of action, with the numbing effect becoming noticeable within minutes after application. This allows for quick pain relief during medical procedures, minimizing patient discomfort.
Short Duration of Action: The duration of action of butamben is relatively short, typically lasting for a few hours. This short duration of action is advantageous for minor procedures that do not require prolonged anesthesia.
Low Systemic Absorption: When used topically as directed, butamben is associated with minimal systemic absorption, reducing the risk of systemic side effects. However, absorption may occur through mucous membranes or damaged skin, potentially leading to systemic effects if large amounts are applied or if it is used on extensive areas of the body.
Minimal Systemic Side Effects: Because of its limited systemic absorption, butamben is generally well-tolerated when used as directed. However, some individuals may experience local reactions at the site of application, such as redness, swelling, or irritation.
Contraindications and Precautions: Butamben should not be used in individuals with known hypersensitivity to the medication or its components. It should also be used with caution in patients with preexisting medical conditions, such as liver or kidney impairment, as well as in pregnant or breastfeeding individuals.
Interaction with Other Medications: Butamben may interact with certain medications, such as other local anesthetics or medications that prolong the QT interval, potentially increasing the risk of adverse cardiac effects. Healthcare professionals should review the patient's medication history and take appropriate precautions when administering butamben.
Patient Education: Patients should be instructed to follow the healthcare provider's instructions regarding the use of butamben, including the appropriate application technique, dosage, and duration of use. They should also be informed about potential side effects and instructed to seek medical attention if they experience any concerning symptoms.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.9 | -0.9 | |
| ADHD | 1.5 | 0.6 | 1.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.7 | 0.71 |
| Allergies | 1.1 | 0.7 | 0.57 |
| Allergy to milk products | 0.3 | -0.3 | |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.2 | 2.9 | -1.42 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 1.2 | |
| Ankylosing spondylitis | 2 | 0.3 | 5.67 |
| Anorexia Nervosa | 0.6 | 1.1 | -0.83 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 2.4 | 1.5 | 0.6 |
| Atherosclerosis | 0.3 | 1 | -2.33 |
| Atrial fibrillation | 1.7 | 0.6 | 1.83 |
| Autism | 3.3 | 3 | 0.1 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.3 | 1.1 | -2.67 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.3 | 0.1 | 2 |
| Carcinoma | 1.4 | 0.9 | 0.56 |
| Celiac Disease | 1 | 1.4 | -0.4 |
| Cerebral Palsy | 0.9 | 0.5 | 0.8 |
| Chronic Fatigue Syndrome | 1.3 | 1.6 | -0.23 |
| Chronic Kidney Disease | 1.8 | 1.4 | 0.29 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.4 | -1.33 |
| Chronic Urticaria (Hives) | 0.6 | 0.3 | 1 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.8 | -1.67 |
| Cognitive Function | 1.7 | 1.1 | 0.55 |
| Colorectal Cancer | 2.3 | 0.8 | 1.87 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.3 | 0.8 | -1.67 |
| COVID-19 | 1.7 | 3.4 | -1 |
| Crohn's Disease | 2.3 | 2 | 0.15 |
| cystic fibrosis | 0.9 | -0.9 | |
| deep vein thrombosis | 0.5 | 0.8 | -0.6 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 2.6 | 2.9 | -0.12 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 1.2 | 1.1 | 0.09 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 0.6 | 0.3 | 1 |
| erectile dysfunction | 0.1 | 0.3 | -2 |
| Fibromyalgia | 1.8 | 0.6 | 2 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 1.7 | -0.31 |
| gallstone disease (gsd) | 0.9 | 0.8 | 0.13 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.6 | -1 |
| Generalized anxiety disorder | 0.6 | 1.1 | -0.83 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.6 | 2 | -2.33 |
| Gulf War Syndrome | 0.3 | 0.3 | 0 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 2.3 | 1.2 | 0.92 |
| Heart Failure | 0.6 | 0.8 | -0.33 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 0 | 0.3 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 2 | 1.6 | 0.25 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 0.9 | 0.6 | 0.5 |
| IgA nephropathy (IgAN) | 0.6 | 1.8 | -2 |
| Inflammatory Bowel Disease | 1.6 | 2.5 | -0.56 |
| Insomnia | 1.2 | 1.4 | -0.17 |
| Intelligence | 0.3 | -0.3 | |
| Intracranial aneurysms | 0.3 | -0.3 | |
| Irritable Bowel Syndrome | 2.6 | 1.7 | 0.53 |
| ischemic stroke | 0.9 | 0.5 | 0.8 |
| Liver Cirrhosis | 2.4 | 2 | 0.2 |
| Long COVID | 1.6 | 2.1 | -0.31 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | -0.6 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.3 | 0.5 | -0.67 |
| ME/CFS without IBS | 0.7 | 1.1 | -0.57 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.5 | -0.25 |
| Metabolic Syndrome | 2 | 2.2 | -0.1 |
| Mood Disorders | 2 | 2 | 0 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.6 | 1.9 | -0.19 |
| Multiple system atrophy (MSA) | 0.1 | 0.3 | -2 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 1 | -2.33 |
| Neuropathy (all types) | 0.6 | 0.5 | 0.2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 1.2 | 0.75 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 3.2 | 2.4 | 0.33 |
| obsessive-compulsive disorder | 0.9 | 2.1 | -1.33 |
| Osteoarthritis | 0.4 | 0.6 | -0.5 |
| Osteoporosis | 1.1 | 0.9 | 0.22 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2 | 3.1 | -0.55 |
| Polycystic ovary syndrome | 1.1 | 1.1 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 1.2 | 0.3 | 3 |
| Primary sclerosing cholangitis | 0.6 | 0.6 | |
| Psoriasis | 1.1 | 0.9 | 0.22 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.7 | 0.65 |
| Rosacea | 0.9 | 0.8 | 0.13 |
| Schizophrenia | 1.5 | 1.4 | 0.07 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.9 | 0.9 | 0 |
| Sleep Apnea | 1.2 | 0.8 | 0.5 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.4 | 1 | 0.4 |
| Systemic Lupus Erythematosus | 0.9 | 1.1 | -0.22 |
| Tic Disorder | 0.3 | 1.2 | -3 |
| Tourette syndrome | 0.9 | 0.9 | |
| Type 1 Diabetes | 0.6 | 1.5 | -1.5 |
| Type 2 Diabetes | 2 | 2.1 | -0.05 |
| Ulcerative colitis | 1.9 | 1.3 | 0.46 |
| Unhealthy Ageing | 2 | 0.8 | 1.5 |
| Vitiligo | 0.9 | 0.3 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
